How to buy Heat Biologics shares

Heat Biologics, Inc is a biotechnology business with stocks listed in the US. Heat Biologics shares (HTBX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$7.91 – a decrease of -INF% over the previous week. Here's how to invest if you're based in Australia.

How to buy shares in Heat Biologics

1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
3. Search for Heat Biologics. Find the share by name or ticker symbol: HTBX. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Heat Biologics reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of US$7.91, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Heat Biologics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Heat Biologics. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Our top pick for

US stocks

eToro Share Trading (US stocks)

Finder Award

Our top pick for

Cheap broker fees

IG Share Trading

Finder Award

Our top pick for

Long-term investing

CMC Markets Stockbroking

Finder Award

Heat Biologics share price

Compare share trading platforms

Sort by:

Name	Product	Standard brokerage for US shares	Inactivity fee	Currency conversion fee	Markets
eToro Share Trading (US stocks) Finder Award		USD 0	USD 10 per month if there’s been no login for 12 months	0.50%	Forex, CFDs, US shares	Zero brokerage share trading on US stocks with trades as low as $50. Note: This broker offers CFDs which are volatile investment products and most clients lose money trading CFDs with this provider. Join the world’s biggest social trading network when you trade stocks, commodities and forex from the one account.	Go to site More Info	Compare	loading Fetching your data...
CMC Markets Stockbroking Finder Award		USD 0	No	0.60%	ASX shares, Global shares, Forex, CFDs, Options trading, mFunds, ETFs, Warrants	$0 brokerage on global shares including US, UK and Japan markets. Trade up to 9,000 products, including shares, managed funds, forex, commodities and cryptocurrencies, plus access up to 15 major global and Australian stock exchanges.	Go to site More Info	Compare	loading Fetching your data...
IG Share Trading Finder Award		USD 0	AUD 50 per quarter if you make fewer than three trades in that period	0.70%	ASX shares, Global shares, Forex, CFDs, Margin trading	$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares. Note: $10,000 deposit required to open account. Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, forex and CFDs, plus get access to 24-hour customer support.	Go to site More Info	Compare	loading Fetching your data...
Saxo Capital Markets (Classic account) Finder Award		USD 9.9	No	0.75%	ASX shares, Global shares, Forex, CFDs, Margin trading, Options trading	High quality, low-cost brokerage on global share trading. Access up to 19,000 global stocks on 36 of the world’s major stock exchanges and enjoy some of the most competitive FX rates on the the market when you trade with Saxo Capital Markets.	Go to site More Info	Compare	loading Fetching your data...

loading

Compare up to 4 providers

Clear selection

Compare

Is it a good time to buy Heat Biologics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Shorting Heat Biologics shares

There are currently 2.0 million Heat Biologics shares held short by investors – that's known as Heat Biologics's "short interest". This figure is 6.2% up from 1.9 million last month.

There are a few different ways that this level of interest in shorting Heat Biologics shares can be evaluated.

Heat Biologics's "short interest ratio" (SIR)

Heat Biologics's "short interest ratio" (SIR) is the quantity of Heat Biologics shares currently shorted divided by the average quantity of Heat Biologics shares traded daily (recently around 5.1 million). Heat Biologics's SIR currently stands at 0.4. In other words for every 100,000 Heat Biologics shares traded daily on the market, roughly 400 shares are currently held short.

However Heat Biologics's short interest can also be evaluated against the total number of Heat Biologics shares, or, against the total number of tradable Heat Biologics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Heat Biologics's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Heat Biologics shares in existence, roughly 90 shares are currently held short) or 0.0915% of the tradable shares (for every 100,000 tradable Heat Biologics shares, roughly 92 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Heat Biologics.

Find out more about how you can short Heat Biologics stock.

Heat Biologics share dividends

We're not expecting Heat Biologics to pay a dividend over the next 12 months.

Have Heat Biologics's shares ever split?

Heat Biologics's shares were split on a 1:7 basis on 11 December 2020. So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Heat Biologics shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Heat Biologics shares which in turn could have impacted Heat Biologics's share price.

Heat Biologics share price volatility

Over the last 12 months, Heat Biologics's shares have ranged in value from as little as US$3.22 up to US$30.1. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Heat Biologics's is 0.166. This would suggest that Heat Biologics's shares are less volatile than average (for this exchange).

Heat Biologics overview

Heat Biologics, Inc., a biopharmaceutical company, focuses on developing immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. The company's T-cell activation platform, includes two variations for intradermal administration, such as immune pan-antigen cytotoxic therapy, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and combination pan-antigen cytotoxic therapy, a dual-acting immunotherapy, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. It is developing HS-110, which is in phase II clinical trials to treat patients with advanced non-small cell lung cancer. The company's preclinical stage products include HS-130 for the treatment of advanced solid tumors; PTX-35, a humanized affinity matured monoclonal antibody, which is a functional agonist of human TNFRSF25 signaling; and PTX-45, a human TL1A-Ig fusion protein that acts as an agonist of TNFRSF25 signaling. Heat Biologics, Inc. has collaboration with Waisman Biomanufacturing to manufacture COVID-19 Vaccine. The company was founded in 2008 and is headquartered in Morrisville, North Carolina.

Frequently asked questions

• What percentage of Heat Biologics is owned by insiders or institutions?

  Currently 3.005% of Heat Biologics shares are held by insiders and 12.271% by institutions.

• When does the fiscal year end for Heat Biologics?

  Heat Biologics's fiscal year ends in December.

• Where is Heat Biologics based?

  Heat Biologics's address is: 627 Davis Drive, Morrisville, NC, United States, 27560

• What is Heat Biologics's ISIN number?

  Heat Biologics's international securities identification number is: US42237K3005

• What is Heat Biologics's CUSIP number?

  Heat Biologics's Committee on Uniform Securities Identification Procedures number is: 42237K102